Novartis Pharmaceutical Manufacturing LLC (manufacturing, primary and secondary packaging, partial quality control, batch release)

The drug is prescribed for the treatment of women with early-stage breast cancer (in combination with an aromatase inhibitor), as well as for the treatment of women with locally advanced or metastatic breast cancer (in combination with an aromatase inhibitor or fulvestrant).

Dosage form: tablets, film-coated

ATC: L01EF02